DURHAM, N.C., March 21, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS ), a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeffrey Abbey, president and chief executive officer, will present at the upcoming 21 st Annual Future Leaders in the Biotech Industry conference. Mr. Abbey will provide a review of progress in the pivotal ADAPT Phase 3 clinical trial for AGS-003, Argos's fully personalized immunotherapy currently in development for the treatment of metastatic renal cell carcinoma, and additional updates for the AGS-004 Phase 2 program in HIV. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York City.
| Event: | 21 st Annual Future Leaders in the Biotech Industry Conference |
| Date: | Friday, March 28, 2014 |
| Time: | 10:30 a.m ET |
A live audio webcast of the presentation can be accessed via the Investors section of the Company's website at www.argostherapeutics.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 14 days following the presentation.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos´ most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com .
Media: Andrea Coan Berry & Company Public Relations (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan (212) 213-0006